Patients must not have a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection that is untreated and/or with a detectable viral load
Patients with known human immunodeficiency virus (HIV) infection, infectious hepatitis, type A, B or C, active hepatitis, or hepatic insufficiency
Previously known infection with human immunodeficiency virus (HIV); or hepatitis B or hepatitis C infection.
History of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection (hepatitis B carriers with normal liver function tests [LFTs] and undetectable viral loads are allowed)
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis A, B, or C (screening is not required).
Active human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C infection.
Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis
Has known human immunodeficiency virus (HIV) and/or Hepatitis B or C infection(s).
Known active Hepatitis B (HepB), Hepatitis C (HepC) or human immunodeficiency virus (HIV) infection.
Known infection with Human Immunodeficiency Virus (HIV), and/or active infection with hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection or known history of tuberculosis
Active human immunodeficiency virus (HIV) or hepatitis B or C infection
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; testing is not required unless clinically suspected
Known Human Immunodeficiency Virus (HIV) infection and/or active Hepatitis B or Hepatitis C infection
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigen–positive) or C (defined as hepatitis C antibody–positive)
No human immunodeficiency virus (HIV) infection or active hepatitis B or C.
Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
Have a symptomatic human immunodeficiency virus infection or symptomatic activated/reactivated hepatitis B or C.
Subject has known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection or is known to be a carrier of hepatitis B or C.
Active infection requiring systemic therapy including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) is NOT permitted
Patients with conditions requiring immunosuppressive medications or chronic infections (including human immunodeficiency virus [HIV] infection, hepatitis B and C)
CRITERIA FOR SCREENING: Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Patients with human immunodeficiency virus (HIV) or active hepatitis B or hepatitis C infection are ineligible
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
Active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Patients with known human immunodeficiency virus (HIV) infection or chronic or acute hepatitis B or C are not eligible; Note: Patients do not need to have HIV, hepatitis B, or hepatitis C testing at screening
Active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV) infection or active hepatitis B or C
Any history of human immunodeficiency virus (HIV) or hepatitis B infection
Patient has a known history of human immunodeficiency virus (HIV) infection or chronic, active hepatitis B (testing not mandatory)
Known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus.
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
No human immunodeficiency virus (HIV) infection or active hepatitis B or C
No known clinical finding or suspicion of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Patients with known human immunodeficiency virus (HIV) infection or hepatitis
Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)
Known positive test for human immunodeficiency virus infection (HIV), or active hepatitis B or hepatitis C infection.
Known active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or cytomegalovirus (CMV)
Has a known history of human immunodeficiency virus (HIV) (HIV1/2 antibodies), hepatitis B, or hepatitis C infection
DONOR: Active human immunodeficiency virus (HIV) or hepatitis B or C infection
Subjects must not have active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; testing is not required as part of this study
Known immunosuppressive disease, autoimmune disease or human immunodeficiency virus infection, hepatitis B or hepatitis C
Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
Be on immunosuppressive therapy or have human immunodeficiency virus (HIV) infection or active hepatitis B or C
Patients with known hepatitis B or C or human immunodeficiency virus (HIV) infection
Known active hepatitis B infection, known history of hepatitis C or human immunodeficiency virus (HIV) infection
Subject has a known infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection
Active hepatitis B or hepatitis C or known human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Patient has known human immunodeficiency virus (HIV) or hepatitis C infection; baseline testing for HIV or hepatitis C is not required
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Known active human immunodeficiency virus (HIV), hepatitis B or C or infection; exception for patients with hepatitis B on antivirals and low viral load, to be determined at the discretion of the investigator
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with a known history of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Positivity for human immunodeficiency virus (HIV)-1/HIV-2, Hepatitis B virus, and Hepatitis C virus active infection
History of chronic or recurrent infection including but not limited to human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Positivity for human immunodeficiency virus (HIV)-1/HIV-2, hepatitis B virus, and hepatitis C virus active infection
In suspected patients no active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with active human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
Patients with known active human immunodeficiency virus (HIV), hepatitis A, hepatitis B, or hepatitis C infection
Hepatitis C infection, chronic infection with hepatitis B, infection with human immunodeficiency virus (HIV), or evidence of hepatic insufficiency
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection are ineligible
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Active infection including human immunodeficiency virus (HIV) and untreated hepatitis B, and hepatitis C. Screening for chronic conditions is not required.
Any evidence of active infection including active Hepatitis B, Hepatitis C or human immunodeficiency virus
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Known infection with hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C.
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection.
No infection with human immunodeficiency virus (HIV) and no known history of hepatitis B or hepatitis C virus indicating acute or chronic infection or active tuberculosis (TB)
Participants who have a known active infection requiring systemic therapy, including human immunodeficiency virus (HIV), hepatitis B, and hepatitis C
Uncontrolled infection with human immunodeficiency virus (HIV) or chronic hepatitis B or C.
Known active infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Known chronic hepatitis B or C, or human immunodeficiency virus (HIV) infection
Known chronic infection with human immunodeficiency virus, hepatitis B, or hepatitis C.
Current infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C. Patients will have serologic testing performed during screening for HIV and hepatitis B and C. Any serologic results suggestive of an ongoing viral infection will be further investigated as necessary to clarify the patient’s status
Patients with a known history of human immunodeficiency virus (HIV) infection or active hepatitis B or hepatitis C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Evidence of active hepatitis B (HepB), hepatitis C (HepC), or Human Immunodeficiency Virus (HIV) infection.
Known human immunodeficiency virus (HIV) or known active hepatitis B or hepatitis C infection for participants not receiving obinutuzumab pretreatment
Active or prior history of human immunodeficiency virus (HIV) infection, hepatitis B or C (screening for all three is mandatory prior to study)
Evidence for infection including wound infections, Human Immunodeficiency Virus (HIV) or any type of Hepatitis
Subject known to have acute or chronic active hepatitis B, hepatitis C, or human immunodeficiency virus infection will also be excluded.
History of human immunodeficiency virus (HIV) infection, active hepatitis B (chronic or acute), or hepatitis C infection
EXCLUSION FOR COLLECTION OF T CELLS/PBMCS: Patients with active human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B
Subject has a known history of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion; for guidance in defining active infection for hepatitis B, please refer to the World Health Organization (WHO) guidelines
Active infection with hepatitis B or C or human immunodeficiency virus (HIV)
Known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis
History of hepatitis B or C, human immunodeficiency virus (HIV), tuberculosis or a chronic infection of any type
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C virus
Known immunodeficiency or human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection; antibody to hepatitis B or C without evidence of active infection may be allowed
Known active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C infection on antiviral treatment
Active infection with hepatitis B or C or human immunodeficiency virus (HIV)
Known infection with human immunodeficiency virus (HIV), hepatitis B or C
Known hepatitis B or C virus, or human immunodeficiency virus (HIV) infection
History of human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection.
Subjects with a known history of hepatitis B or C or human immunodeficiency (HIV) infection.
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV);
Known hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
Active infection including hepatitis B, hepatitis C or human immunodeficiency virus (HIV)
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known human immunodeficiency virus (HIV), hepatitis B and hepatitis C infection
COHORT A: No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C (negative screening tests required)
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV), active hepatitis B or hepatitis C infection
Known infection with human immunodeficiency virus, Hepatitis B, or Hepatitis C
Positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV) infection
Active human immunodeficiency virus (HIV), hepatitis A, B or C infection
Infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
No additional screening intended for human immunodeficiency virus (HIV) or hepatitis infection
Known chronic infection with human immunodeficiency virus (HIV) or viral hepatitis
Known history of human immunodeficiency virus or hepatitis C, or active infection with hepatitis B or C
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection, hepatitis B or Hepatitis C infection
Documented human immunodeficiency virus (HIV), active bacterial infections, active or chronic hepatitis B, or hepatitis C infection
Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; patients should be assessed for high risk behaviors that may result in these infections, such as intravenous drug use or multiple sexual partners; the assessment should be noted
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C; testing is not required in the absence of clinical findings or suspicion
No known active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Active hepatitis or human immunodeficiency virus (HIV) infection
Patients with human immunodeficiency virus (HIV) and active hepatitis B or hepatitis C infection are ineligible
Known Human Immunodeficiency Virus (HIV) infection, chronic hepatitis B or C (unless associated with hepatocellular cancer)
Human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C infection
Patients with human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection
No known human immunodeficiency virus (HIV) infection or chronic hepatitis B or hepatitis C infection
Known history of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C
Evidence of infection with human immunodeficiency virus (HIV) or viral hepatitis
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C.
Active hepatitis B, active hepatitis C, or any human immunodeficiency virus (HIV) infection at the time of screening
Uncontrolled human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Also, known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known diagnosis of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C
Subject has known historical or active infection with HIV (human immunodeficiency virus), hepatitis B, or hepatitis C or subject receiving immunosuppressive or myelosuppressive medications that would, in the opinion of the Investigator, increase the risk of serious neutropenic complications.
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Patients with known human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
Known confirmed diagnosis of human immunodeficiency virus (HIV) infection or active viral hepatitis (hepatitis B or hepatitis C)
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C, or HIV-seropositive
Known human immunodeficiency virus (HIV) or hepatitis B or C infection
Patients with active hepatitis B or C infections or a history of human immunodeficiency virus (HIV) infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; must test during screening if history is not known
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Previously known infection with human immunodeficiency virus (HIV); or, hepatitis B or C requiring treatment;
Known and actively treated infection with human immunodeficiency virus (HIV), hepatitis B or C
Infection with hepatitis B or C, or history of human immunodeficiency virus (HIV) infection, or receiving immunosuppressive or myelosuppressive
Known human immunodeficiency virus (HIV) infection or active hepatitis B (defined as hepatitis B surface antigen–positive) or C (defined as hepatitis C antibody–positive)
Patient with known historical or active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; negative screening tests for HIV, hepatitis B, and hepatitis C are required
History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C infection
Known active hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection.
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C. Testing is not required in the absence of clinical findings or suspicion.
Active Human Immunodeficiency Virus (HIV) or hepatitis B or C infection
Infection with human immunodeficiency virus, hepatitis B, or hepatitis C
Subjects may not have known human immunodeficiency virus (HIV), active hepatitis A, or hepatitis B or C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Known or suspected human immunodeficiency virus (HIV) or hepatitis A(acute), B or C infection
No active or chronic infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Known history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C; testing for these is not required at baseline
Known human immunodeficiency virus, Hepatitis B or Hepatitis C infection.
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C due to confounding effects on immune system
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection due to confounding effects on immune function
Patients with human immunodeficiency virus infection, hepatitis B, or hepatitis C infection
Known human immunodeficiency virus (HIV) infection or chronic hepatitis B or C
Patients with clinically significant infection, including known human immunodeficiency virus (HIV), human herpesvirus-8 (HHV-8), hepatitis C infection, or known hepatitis B surface antigen positivity are not eligible
Patients with active hepatitis B, hepatitis C, or human immunodeficiency virus (HIV) infection
Patients with known human immunodeficiency virus (HIV) infection or viral hepatitis
Have a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies), hepatitis B, or hepatitis C infection
History of or current human immunodeficiency virus (HIV) or hepatitis C virus infection
History of known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
History of known active infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
Known history of or known active infection with human immunodeficiency virus (HIV), hepatitis B or hepatitis C
Known history of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C
History of human immunodeficiency virus (HIV), hepatitis B, or active hepatitis C infection
Known immunosuppressive disease, autoimmune condition, and/or chronic viral infection (eg, human immunodeficiency virus [HIV], hepatitis)
History of or active hepatitis B or hepatitis C or human immunodeficiency virus (HIV) infection
Patient has a known history of human immunodeficiency virus (HIV) or active hepatitis B or active hepatitis C infection (testing not mandatory)
Known positive test for human immunodeficiency virus (HIV), hepatitis C virus, or acute or chronic hepatitis B infection
Active viral hepatitis or symptomatic human immunodeficiency virus (HIV) infection
Participants with known human immunodeficiency virus (HIV) infection, hepatitis B carrier state or with clinical evidence of hepatitis B
Known human immunodeficiency virus (HIV) seropositive or known hepatitis B or hepatitis C infection.
Is previously diagnosed human immunodeficiency virus (HIV) infection or active hepatitis B or C.
Human immunodeficiency virus (HIV), or active hepatitis B or C infection
